Intersafe Professional Safety Management

Implicit Bioscience, located in Woolloongabba, Queensland, is a pioneering company focused on transforming immunotherapy with its lead therapeutic candidate, IC14, an investigational anti-CD14 monoclonal antibody. The company aims to regulate inflammatory responses to infections and injuries, particularly targeting conditions like motor neurone disease and acute respiratory distress syndrome. With a team of world leaders in medical research and clinical practice, Implicit Bioscience is currently involved in notable clinical trials, including studies on heart failure and COVID-19. Their innovative approach seeks to address chronic diseases resulting from inappropriate inflammation, positioning them at the forefront of new therapeutic developments in immunology. Generated from the website